Alendronate decreases BMD loss in prostate cancer By Sally Robertson.

All patients also took calcium 1 g and vitamin D 400 IU once daily. As reported in European Urology, the mean backbone BMD increased by 1.7 percent from baseline in the alendronate group, compared with a 1.9 percent decrease from baseline in the placebo group. Likewise, the mean total hip BMD increased by 0.7 percent in the alendronate group although it decreased by 1.6 percent in the placebo group. The team also observed significantly better improvements in markers for bone desorption as well for bone formation and turnover. The bone resorption marker, cross-linked N-telopeptide of type I collagen , was decreased by a median of 3.5 percent in the alendronate group and elevated by a median of 16.5 percent in the placebo group.

All centers delivered samples from patients who experienced received a medical diagnosis of lung cancer in a non-consecutive manner, and there was no stratification relating to sex, performance status, cigarette smoking history, or previous treatment. A data source and a case-record form were sent and made to all participating hospitals. Progression-free survival was thought as survival without disease progression or death and was calculated from the start of erlotinib therapy until the first observation of disease progression.All centers delivered samples from patients who experienced received a medical diagnosis of lung cancer in a non-consecutive manner, and there was no stratification relating to sex, performance status, cigarette smoking history, or previous treatment. A data source and a case-record form were sent and made to all participating hospitals. Progression-free survival was thought as survival without disease progression or death and was calculated from the start of erlotinib therapy until the first observation of disease progression.